Teva Pharmaceutical Industries Ltd (NYSE:TEVA) gapped down prior to trading on Wednesday . The stock had previously closed at $12.56, but opened at $12.10. Teva Pharmaceutical Industries shares last traded at $11.44, with a volume of 46912084 shares.

Several brokerages recently commented on TEVA. Wells Fargo & Co reissued a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Friday, May 10th. Royal Bank of Canada set a $19.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a report on Friday, May 3rd. BMO Capital Markets set a $17.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a report on Friday, May 3rd. Morgan Stanley set a $16.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a report on Friday, May 3rd. Finally, Cantor Fitzgerald upped their target price on shares of Teva Pharmaceutical Industries from $16.00 to $25.00 and gave the stock a “neutral” rating in a report on Friday, May 3rd. Three investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. Teva Pharmaceutical Industries presently has an average rating of “Hold” and an average price target of $20.53.

The firm has a market capitalization of $12.44 billion, a PE ratio of 4.09, a price-to-earnings-growth ratio of 1.54 and a beta of 1.30. The company has a current ratio of 0.96, a quick ratio of 0.62 and a debt-to-equity ratio of 1.66.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Thursday, May 2nd. The company reported $0.57 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.55 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 18.66% and a positive return on equity of 16.84%. The business had revenue of $4.30 billion during the quarter, compared to analyst estimates of $4.38 billion. During the same quarter in the prior year, the firm earned $0.94 earnings per share. The company’s revenue for the quarter was down 15.2% compared to the same quarter last year. Analysts predict that Teva Pharmaceutical Industries Ltd will post 2.26 earnings per share for the current fiscal year.

In related news, VP Richard Daniell sold 2,098 shares of the company’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $16.88, for a total value of $35,414.24. Following the completion of the sale, the vice president now owns 2,098 shares of the company’s stock, valued at $35,414.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Deborah A. Griffin sold 4,107 shares of the company’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $16.88, for a total transaction of $69,326.16. Following the completion of the sale, the insider now directly owns 2,941 shares of the company’s stock, valued at approximately $49,644.08. The disclosure for this sale can be found here. Insiders sold 11,650 shares of company stock valued at $193,325 in the last three months. 0.49% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Ellington Management Group LLC acquired a new position in Teva Pharmaceutical Industries in the first quarter valued at about $481,000. National Pension Service lifted its position in Teva Pharmaceutical Industries by 3.3% in the first quarter. National Pension Service now owns 1,289,663 shares of the company’s stock valued at $20,222,000 after buying an additional 40,920 shares during the last quarter. Cresset Asset Management LLC acquired a new position in Teva Pharmaceutical Industries in the first quarter valued at about $303,000. Voya Investment Management LLC lifted its position in Teva Pharmaceutical Industries by 4.4% in the first quarter. Voya Investment Management LLC now owns 122,621 shares of the company’s stock valued at $1,923,000 after buying an additional 5,170 shares during the last quarter. Finally, OLD Mission Capital LLC acquired a new position in Teva Pharmaceutical Industries in the first quarter valued at about $193,000. 67.00% of the stock is owned by hedge funds and other institutional investors.

WARNING: This news story was published by Marea Informative and is the sole property of of Marea Informative. If you are accessing this news story on another site, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.mareainformativa.com/news/2019/05/15/teva-pharmaceutical-industries-teva-shares-gap-down-to-12-10.html.

Teva Pharmaceutical Industries Company Profile (NYSE:TEVA)

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

See Also: Green Investing

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.